Zelgen(SH:688266) Ge Long Hui A P P·2025-08-21 09:06Group 1 - The company Zai Lab (688266.SH) has received approval from the National Medical Products Administration for clinical trials of ZG005 and ZGGS18 in combination with JAK inhibitor for advanced solid tumors [1] - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody, classified as a Class 1 innovative tumor immunotherapy product, and is among the first in the world to enter clinical research for this target [1] - ZGGS18 is a recombinant humanized bispecific antibody fusion protein targeting VEGF/TGF-β, also classified as a Class 1 therapeutic biological product, with potential as an innovative treatment for solid tumors [1] Group 2 - The JAK inhibitor, previously known as JAK inhibitor, is a novel dual inhibitor of JAK and ACVR1 developed by the company, classified as a Class 1 new drug, with the company holding independent intellectual property rights for this product [1]